L eft ventricular assist devices (LVADs) have become a standard therapeutic option for select patients with endstage heart failure (HF) refractory to medical therapy. 1, 2 The use of LVADs, either as bridge to transplantation or as destination therapy, has resulted in marked improvement of morbidity and mortality in these patients. [3] [4] [5] [6] [7] [8] Better outcomes observed over the past decade can be attributed to greater experience of LVAD teams in the management of these devices, as well as to the introduction of newer second and third generation continuous-flow LVADs (CF-LVADs), which are smaller, more reliable, and durable. [9] [10] [11] [12] [13] relationship between pulsatility and the risk of gastrointestinal (GI) bleeding from arteriovenous malformations (AVMs). AVMs have been a known frequent source of GI bleeding since early experiences with the use of CF-LVADs. 18, 19 It has been suggested that reduced pulse pressure induced by CF-LVADs results in hypoperfusion of the GI mucosa and neovascularization with friable vessels prone to bleeding. Similar phenomenon, the Heyde syndrome, has also been described in patients with severe aortic stenosis, a scenario with hemodynamic parallels to CF-LVADs. 20 Bleeding in CF-LVAD supported patients represents a challenge for treating physicians because it requires reduction or complete reversal of anticoagulation, which represents a risk of thromboembolic events, including pump thrombosis. In some patients achieving control of bleeding complications can be difficult, even after implementation of standard medical strategies. Anecdotal experience suggests that reducing LVAD speed to increase pulsatility might decrease the risk of bleeding. 18 However, evidence supporting the effectiveness of such approach or the effects of different degrees of pulsatility on the incidence of bleeding in patients with CF-LVADs is limited. The aim of this study was to evaluate the impact of different degrees of pulsatility, as assessed by the LVAD pulsatility index (PI), on the incidence of nonsurgical bleeding among patients supported with the CF-LVAD HeartMate II.
Methods

Study Population
The Utah Transplantation Affiliated Hospitals (U.T.A.H.) HF and transplant program databases were used to identify patients with endstage HF who received an implant with the CF-LVAD HeartMate II (Thoratec Corp, Pleasanton, CA) for either bridge to heart transplantation or destination therapy between January 2004 and August 2012. All patients met the medical policy guideline of New York Heart Association class III/IV HF. Details of the device characteristics, function, and the approach to surgical implantation have been described elsewhere. 7 Patients on pulsatile-flow LVADs, those with evidence of hemolysis or with follow-up of <8 days were excluded from the study. CF-LVADs other than HeartMate II were also excluded to maintain consistency in the assessment of the different LVAD parameters. The study protocol was approved by the institutional review boards.
Clinical and Laboratory Data
Preoperative clinical, hemodynamic, and laboratory data were abstracted from medical records and our HF and transplant program databases. Baseline laboratory data were collected within 48 hours of LVAD implantation and included platelet count, serum hemoglobin, hematocrit, sodium, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, albumin, brain natriuretic peptide, ABO-blood type, and the international normalized ratio (INR). Follow-up serum hemoglobin, hematocrit, and platelet count were obtained at 1 month and 3 months after LVAD implantation. Followup INR levels represented the average of all the INR levels obtained during the first 3 months after LVAD implant.
Echocardiographic Evaluation
Echocardiograms were performed according to American Society of Echocardiography guidelines and were reviewed by an experienced echocardiographer (O.W.-P.). 21 Left ventricular (LV) ejection fraction and right ventricular (RV) function were visually estimated. RV function was classified as normal or mildly, moderately, or severely decreased. The presence of aortic valve opening was evaluated visually using a 3-beat image capture and with M-mode imaging. Aortic valve opening was assessed in every echocardiogram performed between LVAD implantation and the last follow-up (median of 3.0 [interquartile range 2.0-3.0] echocardiograms). It was graded as full opening, intermittent opening (1-2 openings in 3 LV systoles), or full closure during 3 LV systoles. 22 
LVAD Management and Parameters Assessment
After LVAD implantation, LVAD speed was adjusted to achieve adequate flows (cardiac output) and LV decompression, while maintaining a PI >3.5 whenever possible. The HeartMate II LVAD operates in a fixed speed mode of 6000 to 15 000 revolutions per minute (RPM). Although adjustments of LVAD speed are performed on individual basis, in general, the speed during the first 24 hours is increased under echocardiographic guidance up to 8600 to 9000 RPM to allow for aortic valve opening with a ratio of ≈1:3. Subsequently and before discharge, LVAD speed is optimized based on patient symptoms, clinical events (eg, suction events), and echocardiographic evaluation. The LVAD parameters evaluated included pump flow, which is an estimate of blood flow through the pump based on the rotor speed and the pump power (in watts). The pump flow is expressed in liters per minute, and the range is from 0 to 10. PI is a measurement of pulsatile flow through the pump determined by the native LV contractility and the degree of unloading, which depends on LVAD speed and preload. An increase in LV contractility or an increase in preload results in an increment in ventricular pressure, which causes an increase in pump flow during cardiac systole. The magnitude of these flow pulses is measured, averaged over intervals of 15 seconds, and expressed as PI through the following calculation: (maximum flow−minimum flow)/average flow×10. The PI ranges between 1 and 10 during pump operation and can be obtained by interrogating the device. 23 For the purpose of our analyses, medical records were reviewed, and the values of the different LVAD parameters at each visit were recorded for the first 3 months after implant.
Anticoagulation Protocol
After LVAD implant, once hemostasis was achieved, the patients were started on intravenous heparin. Aspirin 81 to 325 mg/d and warfarin were typically started between days 2 and 5. The INR target was 2 to 3. 24 The use of dipyridamole in our programs was discontinued in 2010.
Clinical Events
Major nonsurgical bleeding events occurring between days 8 and 90 after LVAD implantation represented the primary end point. Major bleeding was defined as an episode of suspected internal or external bleeding resulting in 1 of the following: death, surgical intervention, hospitalization, or transfusion of packed red blood cells. This definition was based on the standard definition of major bleeding by the Interagency Registry of Mechanically Assisted Circulatory Support. 25 We also required a documented decrease in hemoglobin ≥2g/dL. In the specific case of GI bleeding, this was defined by clinical evidence of bleeding (guaiac-positive stool, melena, hematochezia, hematemesis, or the presence of blood in the GI tract on endoscopic evaluation) and a decrease in hemoglobin ≥2g/dL. Patients, who experienced nontraumatic intracranial hemorrhage diagnosed clinically and radiologically, were considered to have a major bleeding irrespective of the hemoglobin level. Hemolysis was defined as a plasma-free hemoglobin value >40 mg/dL, in association with other signs of hemolysis (eg, anemia, hyperbilirubinemia, reduced haptoglobin, serum lactate dehydrogenase ≥1500 U/L or tripling of the previous level, and hemoglobinuria).
Statistical Analysis
For descriptive purposes, patients were stratified according to tertiles of the average PI at different time points (ie, at the first week post-LVAD implantation and at the most recent follow-up). Categorical variables were summarized as frequencies and percentages and were compared by the Pearson χ 2 test or by the Fisher exact test when appropriate. Continuous variables were summarized as median and interquartile range (25th and 75th percentiles). Comparisons between groups were performed by using the Mann-Whitney U test or the Kruskal-Wallis test as appropriate. When the Kruskal-Wallis test was significant, then the Mann-Whitney U test was used for individual comparisons. The probability values for pairwise group comparisons were adjusted for multiplicity by use of the Hommel procedure. Cumulative survival free from nonsurgical bleeding were estimated using Kaplan-Meier survival analysis and compared between groups with the log-rank test. 26, 27 Survival free from nonsurgical bleeding was evaluated for the first 3 months after LVAD implantation. The association of the different risk factors with hazard of the primary outcome was assessed using univariable Cox proportional hazards regression models. 28 A multivariable Cox proportional hazards model was used to determine the independent effect of multiple risk factors on the hazard of the primary outcome. The proportionality assumption was tested using Schöenfeld residuals, and it was found to be satisfied by this test. Variables significant at the P<0.10 level in unadjusted analyses were considered for inclusion; only variables significant at the P<0.05 level based on the likelihood ratio test were retained in the final model. The models examined the effect of the following characteristics: age, sex, body mass index, ABOblood type, HF etiology, type of HF: acute versus chronic, history of diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, bleeding before LVAD placement, New York Heart Association class, need of inotropes, intra-aortic balloon pump, temporary LVAD, Interagency Registry of Mechanically Assisted Circulatory Support profile, mean arterial pressure at baseline, LV ejection fraction, LV dimensions, RV function, serum creatinine, serum albumin, platelet count, and INR levels. In the models, the different LVAD parameters (speed, flow, PI, and power), mean arterial pressure, and aortic valve opening were used as time-dependent covariates. PI was analyzed as a continuous variable, and it was also stratified according to tertiles of all the PI measurements during the first 3 months after LVAD implantation. PI groups were included in all multivariable analyses independently of their significance level in univariable analyses. Hazards ratios (HRs) and 95% confidence intervals (CIs) were generated for both univariable and multivariable analyses as measures of strength of association and precision, respectively. All analyses were performed using STATA software, version 12 (StataCorp LP, College Station, TX).
Results
Patient Characteristics
There were 327 durable LVADs implanted during the study period. Of these, 134 patients met the inclusion criteria and comprised our study group. We excluded patients who were implanted with pulsatile-flow LVADs (n=132), CF-LVADs other than HeartMate II (n=45), those with evidence of hemolysis (n=2), and patients with follow-up of <8 days (n=14). Baseline characteristics of the study group, stratified by tertiles of the average PI during the first week of LVAD support, are summarized in Table 1 . The median age was 60 years, and 78% of patients were men. Approximately half of the patients had ischemic cardiomyopathy (49%) and were implanted as bridge to heart transplantation (51%). Most of the baseline characteristics were similar between groups. Patients with a high PI tended to have a lower serum alanine aminotransferase level compared with patients in the intermediate (median of 28 IU/L versus 36 IU/L; adjusted P=0.06) and low PI (median of 35 IU/L; adjusted P=0.08) groups. With regard to LVAD parameters, the pump speed in patients with low (median of 9400 RPM) and intermediate (median of 9300 RPM) PI was higher compared with patients of high PI (median of 9200 RPM, adjusted P<0.03 for both comparisons). There were no significant changes in LVAD parameters over time during the first 3 months of support.
Nonsurgical Bleeding After LVAD Implantation
During the study period, 33 patients experienced 41 episodes of nonsurgical bleeding. Table 2 summarizes the characteristics of patients who experienced a bleeding event contrasted with patients without bleeding events. Patients who experienced bleeding were older and more likely to have chronic kidney disease, ischemic cardiomyopathy, history of bleeding before LVAD implantation, and higher LV ejection fraction. Most LVAD parameters were comparable between patients with and without bleeding; however, PI was consistently lower throughout the study period in patients who experienced a bleeding event ( Table 3 ).
The GI system was the most frequent source of bleeding, comprising 70% (n=23) of the primary bleeding events and 100% (n=8) of the recurrent events (4 patients had 1 recurrent bleeding event, and 2 patients had 2 recurrent events). The most common source of GI bleeding were AVMs (61%), which included 9 patients with endoscopic evidence of AVMs (4 patients had duodenal AVMs, 2 patients had gastric AVMs, 2 patients had jejunal AVMs, and 1 patient had both gastric and duodenal AVMs) and 5 patients in whom AVMs were suspected clinically when no source of bleeding was identified after extensive workup. Other sources of GI bleeding included the following: erosive gastritis in 2 patients (8.7%), colonic polyps in 2 patients (8.7%), diverticulosis in 2 patients (8.7%), colitis in 1 patient (4.3%), and other in 2 patients (8.7%). Epistaxis was the second most common bleeding complication (21%), followed by genitourinary (3.0%) and intracranial hemorrhage (6.0%) ( Figure 1 ). Patients were transfused a median of 3 [interquartile range 2-6] units of packed red blood cells, and 2 patients with epistaxis and 1 patient with GI bleed required surgical intervention to control the bleeding source. The INR was supratherapeutic at the time of bleeding in 6 patients (18%), including both patients who suffered an intracranial hemorrhage.
Risk of Nonsurgical Bleeding and Pulsatility
PI along with other LVAD parameters can change over time, and we therefore evaluated these parameters using a timedependent Cox regression analyses. Three groups were selected based on the tertiles of the total measurements of PI during the study period: low PI (2.4-4.5), intermediate PI (4.6-5.2), and high PI (5.3-6.6). At 3 months after LVAD implantation, there were significant differences in nonsurgical bleeding rates among patients in the different PI tertiles. Survival free from bleeding at 3 months post-implant was 57% for patients with low PI, 78% for intermediate PI, and 90% for high PI (Figure 2) . Similarly, 3-month survival free from nonsurgical bleeding was stratified by aortic valve opening: full closure (59%), intermittent opening (78%), and full opening of the aortic valve (92%) (Figure 3 ). These results were confirmed in univariable and multivariable Cox regression analyses, which took into consideration additional variables detailed in the Methods section (Table 4 ). After adjustment for potential In an attempt to better define the specific association of PI with AVM-related GI bleeding, a Cox regression univariable analysis was performed using PI as a continuous variable. The results of this analysis showed a significant association between PI and the risk of AVM-related GI bleeding (HR, 0.35; 95% CI, 0.19-0.64; P=0.001).
Hematologic Tests After LVAD Implantation
Changes in hemoglobin and hematocrit levels were examined in LVAD recipients stratified by tertiles of the most recent PI (low PI: 2. 
Discussion
The main finding of our study is the demonstration of increased risk of nonsurgical bleeding in CF-LVAD supported patients who had reduced pulsatility. We found that nonsurgical bleeding in the first 3 months after LVAD implantation was associated with low PI. Further, evaluation of pulsatility by means of the echocardiographic assessment of aortic valve opening showed a trend toward increased risk of bleeding in LVAD recipients who had full closure of the aortic valve compared with those who had full opening of the aortic valve. Similar to other studies, we observed a high incidence of bleeding complications in patients with CF-LVADs. 11, 18, 19, 29, 30 Twenty-five percent of our patients were affected by a major bleeding event. The main cause of bleeding was GI bleeding, with AVMs being the most common source. The occurrence of bleeding during circulatory support with CF-LVADs is important for numerous reasons. First, the number of patients on LVAD support continues to grow worldwide, and consequently the number of bleeding events is expected to increase. Second, bleeding is the main cause of morbidity in CF-LVAD supported patients. This is particularly important in the current era of mechanical circulatory support in which implantation of LVADs in patients with lower acuity is being considered and evaluated in clinical trials. Third, transfusion of blood products frequently used in the management of bleeding can have negative repercussions, particularly, in patients awaiting heart transplantation (eg, allosensitization). Finally, hospitalizations, management, and workup of bleeding complications might result in a significant increase of cost. Therefore, identification of factors that increase the risk of bleeding and identification of approaches directed at reducing the incidence of bleeding could lead to changes in clinical practice.
The need for anticoagulation in patients with CF-LVADs was initially suggested as the factor leading to bleeding complications. Crow et al 31 showed increased rates of bleeding in patients supported with CF-LVADs compared with patients not requiring anticoagulation on pulsatile-flow LVADs (63 events/100 patient-years versus 6.8 events/100 years). However, the incidence of bleeding complications was higher than what would be expected based on systemic anticoagulation use alone. In addition, bleeding events occurred even in the absence of supratherapeutic anticoagulation, 30, 32 a fact also seen in our study where 82% of the patients with bleeding had an INR within the desired therapeutic range. Other factors have been implicated in the increased incidence of bleeding in CF-LVADs, including the development of acquired von Willebrand syndrome, 14, 16, 17, 33, 34 impairment in platelet aggregation, 15 and the lack of pulsatility. The potential role of the first 2 factors in the bleeding diathesis observed in patients with CF-LVADs has been investigated; however, the role of pulsatility in this setting is less clear. Data suggesting that changes in pulsatility might have an impact on bleeding have so far been limited to anecdotal reports of better control of bleeding in response to inotropic agent use and LVAD speed reduction. 18, 30 We therefore addressed this issue by systematically and comprehensively evaluating various LVAD parameters and clinical patient characteristics. We used the LVAD-derived parameter PI to evaluate pulsatility. The PI represents the balance of native ventricular function and unloading by the CF-LVAD, and similar to the pulse pressure, it has been shown to be inversely correlated with LVAD assist ratio in preclinical studies. 35, 36 Although the absolute measure of association with directly measured flow or pressure is unknown, it is likely to correlate with such direct measures. In our study, we demonstrated a strong association between reduced PI and bleeding complications. After adjustment in a multivariable analysis, including the intensity of anticoagulation, patients with low PI had over a 4-fold increase in risk of nonsurgical bleeding compared with patients with high PI. The assessment of PI was similarly important when focusing our analysis on patients with AVM-related GI bleeding. A lower PI was associated with an increased risk of AVMrelated GI bleed. These results were further supported by the finding of a strong trend toward an increase in bleeding events in patients with full closure of the aortic valve. The association between aortic valve opening and pulsatility has been previously quantified; aortic valve opening >65% of the time has been associated with a pulse pressure >15 mm Hg, whereas aortic valve opening only 24% of the time has been associated with pulse pressures <15 mm Hg. 37 In our patients, full closure of the aortic valve was associated with over a 4-fold increase in the risk of nonsurgical bleeding; however, this association was not statistically significant after adjustment for multiplegroup comparisons. History of ischemic cardiomyopathy, which was independently associated with an increased risk of bleeding in our study, has been previously linked to the occurrence of AVM-related GI bleed. 38 Furthermore, certain proteins associated with the development of hereditary hemorrhagic telangiectasia might also play a role in atherogenesis and plaque progression. 39 It has been previously shown that patients with blood type O have lower levels of measured von Willebrand factor and factor VIII; however, in our study the presence of blood type O was not associated with an increased risk of bleeding. 40 Although not significant after multivariable adjustment, the following additional clinical characteristics showed strong association with bleeding complications after LVAD implantation: age, renal dysfunction, and severe RV failure (Table 4 ). Patient age and history of chronic kidney disease have been previously linked with an increased bleeding risk in different clinical settings. 41, 42 The association between severe RV dysfunction and increased bleeding risk could be related to a more advanced stage of HF in patients with severe RV dysfunction. Furthermore, patients with significant RV dysfunction can present clinically with low LVAD flows and low PI, which could explain an association between RV dysfunction Figure 1 . Distribution of bleeding complications among patients on continuous-flow left ventricular assist devices stratified by tertiles of the most recent pulsatility index (PI). The most recent PI was the average PI at the time of last follow-up (90 days) or in those left ventricular assist device recipients who experienced a bleeding event, the average PI before the first bleeding episode. An inverse relationship is observed with PI and the incidence of nonsurgical bleeding. Gastrointestinal (GI) bleeding was the main cause of bleeding complications. Bleeding related to arteriovenous malformations (AVMs) was the main contributor to nonsurgical bleeding in patients with reduced pulsatility. GU indicates genitourinary; and ICH, intracranial hemorrhage. and bleeding risk by means of reduced pulsatility in these patients. Nonetheless, the significance of these associations needs to be further explored.
Finally, we demonstrated the presence of persistent anemia in patients with low PI at 3 months of LVAD implantation. This confirms our clinical findings and highlights the negative consequences of bleeding complications (such as chronic anemia) on this population.
Study Limitations
Our study has limitations related to its retrospective design. Although our clinical end point was less likely to be underreported because of the clinical significance of these events and of the fact that the reporting of such bleeding events is mandatory for the Interagency Registry of Mechanically Assisted Circulatory Support data collection, some events might have been missed. Pulsatility in our study was evaluated by means of the PI, which is not directly measured, but rather is an estimation based on the size of the flow pulse generated by the pump in a cardiac cycle. The assessment of the association between PI and AVM-related GI bleed was limited to a univariable analysis attributable to the limited number of events for this outcome. It is possible that other factors not evaluated in our analyses are potentially associated with both reduced pulsatility and a risk of bleeding; such factors would represent an undetected confounder and might have affected our results. In addition, CF-LVADs different from HeartMate II were excluded from our analyses, which limits our ability to extrapolate these results to other types of devices. Von Willebrand factor levels and platelet functionality were not evaluated in our study. These factors might have been affected by differences in LVAD speed and in shear stress between the study groups. Finally, our study group was followed for 3 months after LVAD implant and whether our results are applicable to longer periods of support will need further evaluation.
Conclusion
Nonsurgical bleeding, and specifically GI bleeding, was common in patients supported with the CF-LVAD HeartMate II. In these patients, reduced pulsatility was associated with an increased risk of nonsurgical bleeding during the first 3 months of LVAD support, as determined by a low PI and full aortic valve closure during systole. Increasing pulsatility might be considered as a strategy to reduce nonsurgical bleeding complications in these patients, and this approach should be tested prospectively.
